M6A methylation is likely to be closely associated with the occurrence and development of tumours. In this study, we demonstrated that the transcription levels of the m6A RNA methylation regulators are closely related to the prognosis of glioma. Univariate Cox analysis was performed on the expression levels of methylation regulators and selected three hub genes in glioma. Next, we systematically compared the expression of these m6A RNA methylation regulators in gliomas with different clinicopathological features. The overall survival (OS) curve of the hub genes was initially established based on TCGA database information. YTHDF1 was selected from the hub genes following survival and prognosis analysis. A nomogram was developed to predict the survival probability. We further performed cell function and in vivo xenograft tumour experiments to further verify its role in tumour progression. Next, based on the miRanda and miRDB databases, we predicted one microRNA, hsa‐mir‐346, that might regulate and bind to 3'UTR of YTHDF1, which was confirmed by our fluorescent enzyme reporter gene experiment. In summary, m6A RNA methylation regulators play a potential role in the progression of gliomas. YTHDF1 may have an essential function in glioma diagnosis, treatment and prognosis.

中文翻译：

---

YTHDF1的预后价值受到mir-3436在胶质瘤中的负调控。

M6A甲基化可能与肿瘤的发生和发展密切相关。在这项研究中，我们证明了m6A RNA甲基化调节剂的转录水平与神经胶质瘤的预后密切相关。对甲基化调节剂的表达水平进行单变量Cox分析，并在神经胶质瘤中选择了三个毂基因。接下来，我们系统地比较了具有不同临床病理特征的神经胶质瘤中这些m6A RNA甲基化调节剂的表达。最初基于TCGA数据库信息建立了毂基因的总体存活（OS）曲线。在生存和预后分析后，从中心基因中选择YTHDF1。开发了诺模图以预测生存概率。我们进一步进行了细胞功能和体内异种移植肿瘤实验，以进一步验证其在肿瘤进展中的作用。接下来，基于miRanda和miRDB数据库，我们预测了一种可能调控并结合YTHDF1的3'UTR的microRNA hsa-mir-346，这已通过我们的荧光酶报告基因实验得到了证实。总之，m6A RNA甲基化调节剂在神经胶质瘤的发展中起着潜在的作用。YTHDF1在神经胶质瘤的诊断，治疗和预后中可能具有重要功能。m6A RNA甲基化调节剂在神经胶质瘤的进展中起潜在作用。YTHDF1在神经胶质瘤的诊断，治疗和预后中可能具有重要功能。m6A RNA甲基化调节剂在神经胶质瘤的进展中起潜在作用。YTHDF1可能在神经胶质瘤的诊断，治疗和预后中起重要作用。